Skip to main content

Table 1 Baseline characteristics of all BC patients with BM and PSM patients

From: Surgery for primary tumor benefits survival for breast cancer patients with bone metastases: a large cohort retrospective study

Category

All patients

Non-surgery (%)

P value

PSM patients

Non-surgery (%)

P value

Surgery (%)

Surgery (%)

Age

  

0.000

  

0.467

< 51

422 (29.0)

610 (24.4)

 

281 (28.6)

282 (26.9)

 

51–78

916 (63.0)

1599 (63.9)

 

676 (64.6)

659 (62.9)

 

> 78

116 (8.0)

293 (11.7)

 

90 (8.6)

106 (10.1)

 

Race

  

0.881

  

0.153

Black

218 (15.0)

390 (15.6)

 

160 (15.3)

142 (13.6)

 

Other

114 (7.8)

196 (7.8)

 

72 (6.9)

93 (8.9)

 

White

1122 (77.2)

1916 (76.6)

 

815 (77.8)

812 (77.6)

 

Sex

  

0.067

  

0.394

Female

1426 (98.1)

2472 (98.8)

 

1032 (98.6)

1027 (98.1)

 

Male

28 (1.9)

30 (1.2)

 

15 (1.4)

20 (1.9)

 

Primary site

  

0.534

  

0.988

Central portion

157 (10.8)

241 (9.6)

 

107 (10.2)

104 (9.9)

 

Upper-inner

149 (10.2)

233 (9.3)

 

106 (10.1)

103 (9.8)

 

Lower-inner

75 (5.2)

145 (5.8)

 

58 (5.5)

62 (5.9)

 

Upper-outer

495 (34.0)

906 (36.2)

 

366 (35.0)

377 (36.0)

 

Lower-outer

114 (7.8)

196 (7.8)

 

79 (7.5)

81 (7.7)

 

Others

464 (31.9)

781 (31.2)

 

331 (31.6)

320 (30.6)

 

Laterality

  

0.512

  

0.457

Left

772 (53.1)

1293 (51.6)

 

548 (52.3)

565 (54.0)

 

Right

682 (46.9)

1209 (48.3)

 

499 (47.7)

482 (46.0)

 

Histological type

  

0.007

  

0.931

Ductal

1143 (78.6)

1971 (78.8)

 

841 (80.3)

845 (80.7)

 

Lobular

264 (18.2)

402 (16.1)

 

170 (16.2)

169 (16.1)

 

Others

47 (3.2)

129 (5.2)

 

36 (3.4)

33 (3.2)

 

Grade

  

0.000

  

0.550

I

111 (7.6)

255 (10.2)

 

87 (8.3)

90 (8.6)

 

II

593 (40.8)

1261 (50.4)

 

478 (45.7)

455 (43.5)

 

III

747 (51.4)

975 (39.0)

 

479 (45.7)

501 (47.9)

 

IV

3 (0.2)

11 (0.4)

 

3 (0.3)

1 (0.01)

 

T stage

  

0.000

  

0.567

T1

178 (12.2)

371 (14.8)

 

133 (12.7)

134 (12.8)

 

T2

650 (44.7)

971 (38.8)

 

458 (43.7)

475 (45.4)

 

T3

307 (21.1)

471 (18.8)

 

206 (19.7)

181 (17.3)

 

T4

319 (21.9)

689 (27.5)

 

250 (23.9)

257 (25.4)

 

N stage

  

0.000

  

0.544

N0 + N1

779 (53.0)

2069 (82.7)

 

715 (68.3)

702 (67.0)

 

N2 + N3

684 (47.0)

433 (17.3)

 

332 (31.7)

345 (33.0)

 

Radiotherapy

  

0.000

  

0.861

No

686 (47.2)

1605 (64.1)

 

556 (53.1)

560 (53.5)

 

Yes

768 (52.8)

897 (35.9)

 

491 (46.9)

487 (46.5)

 

Chemotherapy

  

0.000

  

0.249

No

519 (35.7)

1235 (49.4)

 

422 (40.3)

448 (42.8)

 

Yes

935 (64.3)

1267 (50.6)

 

625 (59.7)

599 (57.2)

 

Brain metastasis

  

0.000

  

0.404

No

1419 (97.6)

2322 (92.8)

 

1014 (96.8)

1007 (96.2)

 

Yes

35 (2.4)

180 (7.2)

 

33 (3.2)

40 (3.8)

 

Liver metastasis

  

0.000

  

0.448

No

1261 (86.7)

1858 (74.3)

 

877 (83.8)

864 (82.5)

 

Yes

193 (13.3)

644 (25.7)

 

170 (16.2)

183 (17.5)

 

Lung metastasis

  

0.000

  

0.162

No

1240 (85.3)

1817 (72.6)

 

863 (82.4)

838 (80.0)

 

Yes

214 (14.7)

685 (27.4)

 

184 (17.6)

209 (20.0)

 

Tumor size, cm

  

0.004

  

0.829

< 2

157 (10.8)

362 (14.5)

 

124 (11.8)

125 (11.9)

 

2–5

796 (54.7)

1333 (53.3)

 

572 (54.6)

584 (55.8)

 

> 5

501 (34.5)

807 (32.3)

 

351 (33.5)

338 (32.3)

 

Breast subtype

  

0.023

  

0.889

HR−/HER2+

91 (6.3)

153 (6.1)

 

62 (5.9)

69 (6.6)

 

HR+/HER2-

963 (66.2)

1703 (68.1)

 

705 (67.3)

695 (66.4)

 

HR+/HER2+

231 (15.9)

429 (17.1)

 

171 (16.3)

168 (16.0)

 

HR−/HER2-

169 (11.6)

217 (8.7)

 

109 (10.4)

115 (11.0)

 

Insurance status

  

0.000

  

0.128

Uninsured

32 (2.2)

123 (4.9)

 

27 (2.5)

17 (1.6)

 

Insured

1422 (97.8)

2379 (95.1)

 

1020 (97.4)

1030 (98.4)

 

Marital status

  

0.000

  

0.760

Unmarried

688 (47.3)

1354 (54.1)

 

529 (50.5)

522 (49.9)

 

Married

766 (52.7)

1148 (45.9)

 

518 (49.5)

525 (50.1)

 
  1. BC breast cancer, BM bone metastases, PSM propensity score matching